Skip to main content

Table 2 adjuvant cehmotherapy

From: Cardiovascular disease events within 5 years after a diagnosis of breast cancer

N = 682 N (%)
Chemotherapy (N = 682)Y256 (37.5%)
 N426 (62.5%)
Neo-adjuvant chemotherapy (N = 682)Y22 (3.2%)
 N660 (96.8%)
Adjuvant chemotherapy (N = 682)Y234 (34.3%)
 N448 (65.7%)
Chemotherapy with anthracyclines (N = 256)Y174 (68%)
 N82 (32%)
3 FEC 100–3 DOCETAXEL (N = 256)Y74 (28.9%)
 N182 (71.1%)
6 TAC (N = 256)Y79 (30.9%)
 N177 (69.1%)
6 FEC (N = 256)Y1 (0.4%)
 N117 (45.7%)
4 AC-4 DOCETAXEL (N = 256)Y19 (7.4%)
 N237 (92.6%)
4 AC-12 PACLITAXEL WEEKLY: (N = 256)Y1 (0.4%)
 N255 (99.6%)
Chemotherapy without anthracyclines (N = 256)Y82 (32%)
 N174 (68%)
6 DOCETAXEL-CARBOPLATINE (N = 256)Y4 (1.6%)
 N251 (98%)
4 DOCETAXEL-ENDOXAN (N = 256)Y78 (30.5%)
N178 (69.5%)